Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBITDA (2019 - 2025)

Historic EBITDA for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$111.9 million.

  • Beam Therapeutics' EBITDA fell 1934.88% to -$111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.6 million, marking a year-over-year decrease of 19727.34%. This contributed to the annual value of -$376.7 million for FY2024, which is 19087.83% down from last year.
  • Per Beam Therapeutics' latest filing, its EBITDA stood at -$111.9 million for Q3 2025, which was down 1934.88% from -$102.4 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year EBITDA high stood at $145.4 million for Q4 2023, and its period low was -$201.6 million during Q1 2021.
  • Moreover, its 5-year median value for EBITDA was -$91.4 million (2024), whereas its average is -$78.6 million.
  • Per our database at Business Quant, Beam Therapeutics' EBITDA crashed by 55408.2% in 2021 and then soared by 50278.35% in 2023.
  • Beam Therapeutics' EBITDA (Quarter) stood at -$64.8 million in 2021, then skyrocketed by 44.26% to -$36.1 million in 2022, then skyrocketed by 502.78% to $145.4 million in 2023, then plummeted by 162.87% to -$91.4 million in 2024, then decreased by 22.44% to -$111.9 million in 2025.
  • Its EBITDA stands at -$111.9 million for Q3 2025, versus -$102.4 million for Q2 2025 and -$109.8 million for Q1 2025.